CytoSorbents Corporation announced that Dr. Phillip Chan, Chief Executive Officer, would present at the 12th Annual Healthcare Conference at the Rodman & Renshaw Global Investment Conference. The conference will take place at the New York Palace Hotel in New York, New York from September 12 to 15, 2010. Dr. Chan’s presentation will take place on Tuesday, September 14, 2010 at 5:45PM EDT in the Winslow Salon.
An audio webcast of the slide presentation will be available for 90 days after the event at http://www.wsw.com/webcast/rrshq18/ctso. An electronic copy of the presentation will be made available upon email request. Those interested can check the conference schedule for any scheduling updates at http://www.rodmanandrenshaw.com/conferences?id=51.
Headquartered in Monmouth Junction, New Jersey, CytoSorbents Corporation, and their operating subsidiary CytoSorbents, Inc., is a critical care focused therapeutic device company in clinical trials to treat severe sepsis, often called “overwhelming infection,” with a novel blood purification device called CytoSorb™. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. It is the body’s abnormal immune response to the trigger that leads to severe inflammation and the unregulated, massive production of cytokines, often called “cytokine storm,” that then causes multi-organ failure and often death.
CytoSorb™ is a cartridge containing highly porous polymer beads designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped repeatedly through the CytoSorb™ cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient.
CytoSorbents Corporation is currently conducting their European Sepsis Trial. This is a multi-center, randomized, controlled clinical trial using CytoSorb™ to treat up to 100 patients with severe sepsis in the setting of respiratory failure. The Company, pending a successful trial, will seek CE Mark approval and commercialization of CytoSorb™ in the European Union.
For more information visit: www.cytosorbents.com
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment